MY155029A - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents

Peptide vaccines for cancers expressing tumor-associated antigens

Info

Publication number
MY155029A
MY155029A MYPI20093446A MYPI20093446A MY155029A MY 155029 A MY155029 A MY 155029A MY PI20093446 A MYPI20093446 A MY PI20093446A MY PI20093446 A MYPI20093446 A MY PI20093446A MY 155029 A MY155029 A MY 155029A
Authority
MY
Malaysia
Prior art keywords
peptides
present
associated antigens
expressing tumor
peptide vaccines
Prior art date
Application number
MYPI20093446A
Other languages
English (en)
Inventor
Tsunoda Takuya
Ohsawa Ryuji
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MY155029A publication Critical patent/MY155029A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
MYPI20093446A 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens MY155029A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
MY155029A true MY155029A (en) 2015-08-28

Family

ID=39709837

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2012004306A MY173379A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
MYPI20093446A MY155029A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MYPI2012004306A MY173379A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Country Status (27)

Country Link
EP (20) EP2465864B1 (OSRAM)
JP (6) JP5239103B2 (OSRAM)
KR (8) KR101511134B1 (OSRAM)
CN (4) CN102863514B (OSRAM)
AR (1) AR068302A1 (OSRAM)
AU (1) AU2008218463B2 (OSRAM)
BR (1) BRPI0808421B1 (OSRAM)
CA (3) CA2992074C (OSRAM)
CO (1) CO6190536A2 (OSRAM)
CY (2) CY1114590T1 (OSRAM)
DK (3) DK2476694T3 (OSRAM)
ES (6) ES2530777T3 (OSRAM)
HR (3) HRP20131044T1 (OSRAM)
IL (10) IL200478A (OSRAM)
MX (4) MX337456B (OSRAM)
MY (2) MY173379A (OSRAM)
NZ (4) NZ602122A (OSRAM)
PH (1) PH12014501642B1 (OSRAM)
PL (3) PL2465864T3 (OSRAM)
PT (2) PT2465864E (OSRAM)
RU (1) RU2464275C2 (OSRAM)
SG (3) SG10201909675QA (OSRAM)
SI (3) SI2465864T1 (OSRAM)
TW (5) TWI610939B (OSRAM)
UA (1) UA100372C2 (OSRAM)
WO (1) WO2008102557A1 (OSRAM)
ZA (1) ZA200905881B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019475A2 (en) 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
CN101827936B (zh) 2007-08-20 2014-12-10 肿瘤疗法科学股份有限公司 Cdh3肽以及含有cdh3肽的药剂
EP2313504B1 (en) 2008-06-30 2015-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
RU2532105C2 (ru) * 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
RU2011130796A (ru) 2008-12-24 2013-01-27 Онкотерапи Сайенс, Инк. Пептиды c1orf59 и содержащие их вакцины
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
TWI538685B (zh) * 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
TWI618541B (zh) 2010-12-02 2018-03-21 腫瘤療法 科學股份有限公司 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
CN104144707B (zh) * 2011-12-14 2018-09-14 得克萨斯系统大学董事会 用于癌症疗法的连带基因失活生物标志和靶标
KR20140138900A (ko) * 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
WO2014010231A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
JP6255594B2 (ja) * 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
ES2662808T3 (es) * 2012-08-31 2018-04-09 Vasculead Inc. Péptido obtenido de PSF1
AU2013317194B2 (en) 2012-09-11 2018-07-12 Oncotherapy Science, Inc. UBE2T peptides and vaccines containing the same
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US20160166666A1 (en) * 2013-07-12 2016-06-16 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US10576097B2 (en) * 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
AU2017240745B2 (en) * 2016-03-31 2021-08-19 Biontech Us Inc. Neoantigens and methods of their use
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
JP7289289B2 (ja) * 2017-03-28 2023-06-09 ツェンラン・チュー 腫瘍性疾患を治療する方法
EP3666888A4 (en) * 2017-08-10 2021-09-01 Good T Cells, Inc. T-CELL ACTIVATION METHOD FOR CANCER TREATMENT
KR102267463B1 (ko) * 2018-02-15 2021-06-21 코쿠리츠다이가쿠호진 아사히카와 이카다이가쿠 암 항원 펩티드
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) * 2019-12-31 2021-07-16 上海细胞治疗集团有限公司 一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995028484A1 (en) * 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100631766B1 (ko) * 1997-10-07 2006-10-09 오노 야꾸힝 고교 가부시키가이샤 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및그들의 용도
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU1220001A (en) * 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
AU2002309583A1 (en) * 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005536186A (ja) * 2002-03-07 2005-12-02 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管および血管内皮細胞遺伝子
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2004055050A2 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
US20070253954A1 (en) * 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
EP2520652B1 (en) * 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
JP2008509654A (ja) * 2004-06-01 2008-04-03 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
AU2006216683A1 (en) * 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
DK2325306T3 (en) * 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
JP4803460B2 (ja) * 2005-08-09 2011-10-26 学校法人 久留米大学 Ｈｌａ−ａ２４分子結合性扁平上皮癌抗原由来ペプチド
RU2395519C2 (ru) * 2005-08-09 2010-07-27 Онкотерапи Сайенс, Инк. Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
WO2007064743A2 (en) * 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
ES2487637T3 (es) * 2006-04-10 2014-08-22 Genentech, Inc. Moduladores de PDZ Disheveled
ATE509096T1 (de) * 2006-06-16 2011-05-15 Onco Therapy Science Inc Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
CN101827936B (zh) * 2007-08-20 2014-12-10 肿瘤疗法科学股份有限公司 Cdh3肽以及含有cdh3肽的药剂
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2011039289A1 (de) * 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
SI2476694T1 (sl) 2015-02-27
SG10201506589WA (en) 2015-09-29
EP2570430A3 (en) 2013-07-10
JP2014210804A (ja) 2014-11-13
JP2013091645A (ja) 2013-05-16
AU2008218463A1 (en) 2008-08-28
PH12014501642A1 (en) 2015-12-02
EP2476692A2 (en) 2012-07-18
EP2583976A3 (en) 2013-10-23
CN101663315A (zh) 2010-03-03
KR101644871B1 (ko) 2016-08-02
PT2121731E (pt) 2013-10-24
KR20150064236A (ko) 2015-06-10
EP2121731A4 (en) 2010-04-21
KR20090121349A (ko) 2009-11-25
EP2594581A3 (en) 2013-08-14
JP2010519176A (ja) 2010-06-03
IL200478A (en) 2015-11-30
JP5239103B2 (ja) 2013-07-17
IL219047A0 (en) 2012-05-31
EP2476693A2 (en) 2012-07-18
PT2465864E (pt) 2015-01-14
EP2567971A2 (en) 2013-03-13
EP2570429A2 (en) 2013-03-20
IL219048A (en) 2015-07-30
HRP20131044T1 (hr) 2013-12-06
ZA200905881B (en) 2010-05-26
IL219041A (en) 2014-12-31
DK2121731T3 (da) 2013-10-21
CN104292299B (zh) 2017-09-29
EP2567971A3 (en) 2013-06-26
KR20150116463A (ko) 2015-10-15
TWI610939B (zh) 2018-01-11
IL219040A0 (en) 2012-05-31
ES2530777T3 (es) 2015-03-05
EP2570428A2 (en) 2013-03-20
EP2476692A3 (en) 2012-12-19
NZ602122A (en) 2014-03-28
EP2465867B1 (en) 2015-04-01
EP2476692B1 (en) 2015-04-15
EP2476694A2 (en) 2012-07-18
UA100372C2 (ru) 2012-12-25
TW201422637A (zh) 2014-06-16
ES2540893T3 (es) 2015-07-14
IL219042A0 (en) 2012-05-31
IL219043A (en) 2014-12-31
KR20140130507A (ko) 2014-11-10
HK1172041A1 (en) 2013-04-12
JP2013116895A (ja) 2013-06-13
EP2476693A3 (en) 2012-10-03
WO2008102557A1 (en) 2008-08-28
RU2464275C2 (ru) 2012-10-20
CA2919248A1 (en) 2008-08-28
KR101543623B1 (ko) 2015-08-11
IL219044A (en) 2014-12-31
TW201538522A (zh) 2015-10-16
EP2121731B1 (en) 2013-08-14
CY1115841T1 (el) 2017-01-25
HK1134507A1 (en) 2010-04-30
EP2465866A2 (en) 2012-06-20
EP2570430A2 (en) 2013-03-20
HK1172345A1 (en) 2013-04-19
TWI596109B (zh) 2017-08-21
PH12014501642B1 (en) 2015-12-02
IL219044A0 (en) 2012-05-31
CY1114590T1 (el) 2016-10-05
AU2008218463B2 (en) 2013-01-17
TW201433574A (zh) 2014-09-01
EP2594581A2 (en) 2013-05-22
IL219042A (en) 2016-03-31
EP2476693B1 (en) 2014-12-24
EP2565203A1 (en) 2013-03-06
SI2121731T1 (sl) 2013-10-30
KR101511140B1 (ko) 2015-04-10
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
DK2476694T3 (en) 2014-12-08
EP2465867A3 (en) 2012-10-10
JP5608953B2 (ja) 2014-10-22
EP2476695A3 (en) 2012-12-12
IL219048A0 (en) 2012-05-31
EP2594582A3 (en) 2013-08-14
KR20130023407A (ko) 2013-03-07
HK1172042A1 (en) 2013-04-12
HRP20150108T1 (hr) 2015-05-08
CN104292299A (zh) 2015-01-21
NZ602119A (en) 2014-03-28
CA2992074A1 (en) 2008-08-28
CO6190536A2 (es) 2010-08-19
CN103351423B (zh) 2016-09-28
MX337456B (es) 2016-03-03
AR068302A1 (es) 2009-11-11
MX2009009022A (es) 2010-03-03
PL2121731T3 (pl) 2014-01-31
EP2465864A3 (en) 2012-10-03
EP2574623A2 (en) 2013-04-03
HK1172043A1 (en) 2013-04-12
ES2541863T3 (es) 2015-07-27
DK2465864T3 (en) 2014-11-24
CA2992074C (en) 2021-01-05
CN103351423A (zh) 2013-10-16
PL2465864T3 (pl) 2015-03-31
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
EP2574623A3 (en) 2013-07-17
TWI438207B (zh) 2014-05-21
EP2465866A3 (en) 2012-10-10
BRPI0808421B1 (pt) 2021-10-05
TWI615403B (zh) 2018-02-21
PL2476694T3 (pl) 2015-04-30
IL219043A0 (en) 2012-05-31
CN101663315B (zh) 2014-10-15
EP2465864B1 (en) 2014-10-08
EP2121731A1 (en) 2009-11-25
KR101540000B1 (ko) 2015-07-29
JP5614761B2 (ja) 2014-10-29
ES2527397T3 (es) 2015-01-23
SI2465864T1 (sl) 2014-12-31
JP2016094459A (ja) 2016-05-26
EP2583976A2 (en) 2013-04-24
HK1172346A1 (en) 2013-04-19
IL219041A0 (en) 2012-05-31
EP2465864A2 (en) 2012-06-20
KR101644877B1 (ko) 2016-08-03
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
KR20150018895A (ko) 2015-02-24
EP2573110A3 (en) 2013-09-04
CA2678755C (en) 2016-04-26
MX359680B (es) 2018-09-28
JP5239104B2 (ja) 2013-07-17
KR20160045939A (ko) 2016-04-27
EP2573109A2 (en) 2013-03-27
JP5874158B2 (ja) 2016-03-02
BRPI0808421A2 (pt) 2017-08-29
MX337417B (es) 2016-03-03
JP2010209060A (ja) 2010-09-24
IL219046A (en) 2015-02-26
ES2532708T3 (es) 2015-03-31
EP2465867A2 (en) 2012-06-20
IL200478A0 (en) 2010-04-29
NZ591704A (en) 2012-09-28
KR20140121489A (ko) 2014-10-15
EP2465865A3 (en) 2013-07-24
HRP20141233T1 (hr) 2015-02-27
EP2465865A2 (en) 2012-06-20
EP2570429A3 (en) 2013-08-28
EP2476694A3 (en) 2013-04-24
TWI494319B (zh) 2015-08-01
KR101511134B1 (ko) 2015-04-28
EP2476694B1 (en) 2014-11-19
EP2573110A2 (en) 2013-03-27
ES2435194T3 (es) 2013-12-16
HK1172344A1 (en) 2013-04-19
SG10201909675QA (en) 2019-11-28
EP2573109A3 (en) 2013-06-19
SG179402A1 (en) 2012-04-27
IL219040A (en) 2014-12-31
RU2009135020A (ru) 2011-03-27
TW201623325A (zh) 2016-07-01
NZ579768A (en) 2012-03-30
MY173379A (en) 2020-01-21
IL219045A0 (en) 2012-05-31
EP2465865B1 (en) 2016-11-02
EP2594582A2 (en) 2013-05-22
EP2476695A2 (en) 2012-07-18
TW200844111A (en) 2008-11-16

Similar Documents

Publication Publication Date Title
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
EP2476699A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
DE602007011901D1 (de) Ptiden und zellpenetrierenden peptiden gekoppelt a
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
MX2009007261A (es) Vacuna de peptido foxp3.
MX2010005816A (es) Epítopos de péptido de stat3.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
ES2529713T3 (es) Péptidos anticonceptivos derivados de veneno de araña
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
TH126305A (th) อนุพันธุ์เพพไทด์ vapeehptllteaplnpk ที่มีการกระตุ้นทางชีวภาพ